Tong Hua Dong Bao Insulin To Compete With Novo Nordisk, Eli Lilly
This article was originally published in PharmAsia News
Tong Hua Dong Bao Pharmaceutical projected its 2009 output of recombinant human insulin at 3,000 Kg and aims to compete with Novo Nordisk and Eli Lilly domestically and internationally. Tong Hua Dong Bao invested RMB 600 million in facility expansions, and with the increased output it expects to boost its market share in China 50 percent. In addition, relevant national agencies have tested the quality of Tong Hua Dong Bao's insulin and reported it to be similar to that of Novo Nordisk and Eli Lilly. Tong Hua Dong Bao's product is also at least 30 percent cheaper giving the Chinese company a competitive advantage in the international market. Tong Hua Dong Bao has started targeting affluent oil-producing countries in the Middle East as potential customers. (Click here for more
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.